Wegovy seeks insurance edge in Korea's obesity drug war

What happened: Novo Nordisk Korea applied to the Health Insurance Review and Assessment Service for national health insurance reimbursement of Wegovy, which has been outside the system since its October 2024 Korean launch. Key numbers: Mounjaro held 86.7 percent of Korea's GLP-1 weight-loss market in June; Wegovy 13.2 percent. Why it matters: Reimbursement could lower treatment costs and improve Wegovy's affordability against Mounjaro and Hanmi's Eppe, approved in five dosages last week. An industry official said Mounjaro and Eppe would likely seek the same coverage.

Wegovy pursuing insurance coverage amid Korea's obesity drug competition.

Wegovy pursuing insurance coverage amid Korea's obesity drug competition. — impact context not separately stored; see What changed.